Wedbush Boosts Earnings Estimates for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Research analysts at Wedbush lifted their Q1 2025 earnings estimates for shares of Fennec Pharmaceuticals in a research report issued on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.14). Wedbush currently has a "Outperform" rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.42 EPS and FY2026 earnings at $2.20 EPS.

A number of other equities research analysts also recently weighed in on FENC. Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th.

Fennec Pharmaceuticals Stock Down 2.9 %

Shares of FENC traded down $0.19 during midday trading on Thursday, hitting $6.32. The company had a trading volume of 46,343 shares, compared to its average volume of 112,990. Fennec Pharmaceuticals has a 52 week low of $3.96 and a 52 week high of $11.49. The company's 50 day moving average price is $6.40 and its 200 day moving average price is $5.64. The stock has a market cap of $174.19 million, a price-to-earnings ratio of -63.19 and a beta of 0.36.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company's stock valued at $157,000 after purchasing an additional 22,951 shares during the period. State Street Corp boosted its stake in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company's stock valued at $1,641,000 after purchasing an additional 7,053 shares during the period. Rhumbline Advisers boosted its stake in Fennec Pharmaceuticals by 12.9% during the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company's stock valued at $217,000 after purchasing an additional 3,911 shares during the period. Franklin Resources Inc. boosted its stake in Fennec Pharmaceuticals by 18.7% during the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company's stock valued at $74,000 after purchasing an additional 2,330 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in Fennec Pharmaceuticals during the 4th quarter valued at about $97,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total transaction of $66,600.00. Following the completion of the transaction, the director now directly owns 76,294 shares of the company's stock, valued at $508,118.04. The trade was a 11.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 31,186 shares of company stock valued at $203,389 in the last quarter. Insiders own 10.98% of the company's stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.